Package Leaflet: Information for the Patient
Verzenios 50mg film-coated tablets
Verzenios 100mg film-coated tablets
Verzenios 150mg film-coated tablets
abemaciclib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Verzenios is a medicine used to treat cancer that contains the active substance abemaciclib.
Abemaciclib blocks the effects of certain proteins called cyclin-dependent kinases 4 and 6. These proteins are abnormally active in some cancer cells and make them grow out of control. Blocking the action of these proteins can slow down the growth of cancer cells, reduce the tumor, and delay the progression of cancer.
Verzenios is used to treat certain types of breast cancer (positive for the hormone receptor (HR+) and negative for the human epidermal growth factor receptor 2 (HER2-)) that:
Do not take Verzenios:
Warnings and precautions
Verzenios may:
See section 4 “Possible side effects”, and tell your doctor if you have any symptoms.
What your doctor will check before and during your treatment
You will have regular blood tests before and during treatment to check if Verzenios is affecting your blood (white blood cells, red blood cells, and platelets) or the concentration of liver enzymes in your blood.
Children and adolescents
Verzenios should not be used in children and adolescents under 18 years of age.
Other medicines and Verzenios
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist before taking Verzenios if you are taking any of the following:
Verzenios with food and drink
Avoid grapefruit or grapefruit juice while taking this medicine, as it may increase the concentration of Verzenios in the blood.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take Verzenios if you are pregnant.
Avoid becoming pregnant while taking Verzenios.
If you are of childbearing age, you should use adequate contraceptive measures (such as double-barrier contraception like condoms and diaphragms) during treatment and for at least 3 weeks after finishing treatment. Consult your doctor about the use of contraceptive methods if there is any possibility that you may become pregnant.
Tell your doctor if you become pregnant.
Breastfeeding
Do not breastfeed while taking Verzenios. It is not known if Verzenios passes into breast milk.
Fertility
Verzenios may reduce fertility in men. Talk to your doctor for advice on fertility before treatment.
Driving and using machines
Fatigue and dizziness are very common side effects. If you feel exceptionally tired or dizzy, be extra careful when driving or using machines.
Verzenios contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Verzenios contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet; this is essentially “sodium-free”.
Recommended dose
Follow exactly the instructions of your doctor or pharmacist for taking this medicine. If you are unsure, ask your doctor or pharmacist again.
The recommended dose of Verzenios when given with hormone therapy to treat your breast cancer is 150 mg by mouth twice a day.
If you experience certain side effects while taking Verzenios, your doctor may reduce your dose or interrupt treatment, temporarily or permanently.
When and how to take Verzenios
Take Verzenios twice a day, approximately at the same time every day, preferably in the morning and evening, to have the right amount of medicine in your body during treatment.
You can take the tablets with or without food, just avoid grapefruit and grapefruit juice (see section 2 “Verzenios with food and drink”).
Swallow the tablet whole with a glass of water. Do not chew, crush, or break the tablets before swallowing.
How long to take Verzenios
Take Verzenios continuously for the time your doctor tells you. If you are taking Verzenios for early breast cancer, you should take it for up to 2 years.
If you take more Verzenios than you should
If you take too many tablets, or if someone else takes your medicine, contact your doctor or go to a hospital. Show the Verzenios packaging and this leaflet. You may need medical treatment.
If you forget to take Verzenios
If you vomit after taking the dose or if you forget to take a dose, take the next dose at the usual scheduled time. Do not take a double dose to make up for the forgotten or vomited dose.
If you stop taking Verzenios
Do not stop taking Verzenios unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor immediately if you experience any of the following:
See section 2 for more information on any of the possible side effects listed above.
Other side effects of Verzenios may include:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after “EXP”. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Do not take this medicine if you notice any damage to the packaging or if it shows any signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Verzenios
Appearance and packaging
Verzenios is available in calendar packs for the blister of 14, 28, 42, 56, 70, and 168 film-coated tablets and single-dose precut blisters of 28 x 1 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528BJ Utrecht, Netherlands
Manufacturer
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain
You can ask for more information about this medicine from your local representative of the Marketing Authorisation Holder:
Belgium/België/Belgien Eli Lilly Benelux S.A./N.V. Tel: + 32-(0)2 548 84 84 | Lithuania Eli Lilly Lietuva Tel: +370 (5) 2649600 |
Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tel: + 32-(0)2 548 84 84 | |
Czech Republic ELI LILLY CR, s.r.o. Tel: + 420 234 664 111 | Hungary Lilly Hungária Kft. Tel: + 36 1 328 5100 |
Denmark Eli Lilly Danmark A/S Tel: +45 45 26 60 00 | Malta Charles de Giorgio Ltd. Tel: + 356 25600 500 |
Germany Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222 | Netherlands Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800 |
Estonia Eli Lilly Nederland B.V. Tel: +372 6 817 280 | Norway Eli Lilly Norge A.S. Tel: + 47 22 88 18 00 |
Greece ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600 | Austria Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780 |
Spain Lilly S.A. Tel: + 34-91 663 50 00 | Poland Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00 |
France Lilly France Tel: +33-(0) 1 55 49 34 34 | Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 |
Croatia Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999 | Romania Eli Lilly România S.R.L. Tel: + 40 21 4023000 |
Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377 | Slovenia Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10 |
Iceland Icepharma hf. Tel: + 354 540 8000 | Slovakia Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 111 |
Italy Eli Lilly Italia S.p.A. Tel: + 39- 055 42571 | Finland Oy Eli Lilly Finland Ab Tel: + 358-(0) 9 85 45 250 |
Cyprus Phadisco Ltd Τηλ: +357 22 715000 | Sweden Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800 |
Latvia Eli Lilly (Suisse) S.A Parstavnieciba Latvija Tel: +371 67364000 | United Kingdom (Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).